Williams P D, Laska D A, Tay L K, Hottendorf G H
Department of Experimental Toxicology, Bristol-Myers Company, Syracuse, New York 13221.
Antimicrob Agents Chemother. 1988 Mar;32(3):314-8. doi: 10.1128/AAC.32.3.314.
The rabbit kidney cell line LLC-RK1 was tested for its ability to discriminate the toxicities of six cephalosporin antibiotics according to their in vivo nephrotoxic potentials in rabbits. With the exception of cephalothin, which was markedly toxic to kidney cells in vitro, a good correlation between in vitro toxicity and in vivo nephrotoxicity was obtained, yielding the following toxicity rank order: ceftazidime less than cefazolin approximately cefoperazone less than cephaloglycin approximately cephaloridine. The addition of a kidney microsomal S9 fraction to the cell cultures desacetylated cephalothin as occurs in vivo and detoxified this antibiotic, providing it with the proper toxicity relative to the other cephalosporins. When compared with parent structures, desacetylated derivatives of other cephalosporins such as cephapirin were similarly found to be less toxic to LLC-RK1 cells. The acetylated cephalosporin cephaloglycin was not detoxified by the kidney S9 fraction and was desacetylated three to four times slower than cephalothin by renal esterases. Thus, the rate and extent of desacetylation of cephalosporins may play a role in their in vivo nephrotoxic potential. Our results further suggest that LLC-RK1 cells will provide a useful model for evaluating the potential nephrotoxicity of new cephalosporin antibiotics before in vivo studies.
根据六种头孢菌素抗生素在兔体内的肾毒性潜力,对兔肾细胞系LLC-RK1区分其毒性的能力进行了测试。除了在体外对肾细胞有明显毒性的头孢噻吩外,体外毒性与体内肾毒性之间存在良好的相关性,得出以下毒性等级顺序:头孢他啶<头孢唑林≈头孢哌酮<头孢甘氨酸≈头孢噻啶。向细胞培养物中添加肾微粒体S9组分,可使头孢噻吩像在体内一样脱乙酰化,并使这种抗生素解毒,使其相对于其他头孢菌素具有适当的毒性。与母体结构相比,其他头孢菌素如头孢匹林的脱乙酰化衍生物对LLC-RK1细胞的毒性同样较低。乙酰化的头孢菌素头孢甘氨酸不能被肾S9组分解毒,并且被肾酯酶脱乙酰化的速度比头孢噻吩慢三到四倍。因此,头孢菌素的脱乙酰化速率和程度可能在其体内肾毒性潜力中起作用。我们的结果进一步表明,在进行体内研究之前,LLC-RK1细胞将为评估新型头孢菌素抗生素的潜在肾毒性提供一个有用的模型。